IL17A and myalgic encephalomeyelitis/chronic fatigue syndrome: Table 3 shows results for A-ME/CFS cases (excluding those with later malignancies) vs C-ME/CFS cases. In A-ME/CFS vs C-ME/CFS cases, lower levels of IL17A (OR, 0.00; 95% CI, 0.00, 0.85; P=0.047) were strongly associated with A-ME/CFS caseness as were lower levels of CXCL9 (MIG) (OR, 0.48; 95% CI, 0.25, 0.94; P=0.032).